MX2017003550A - Use of cysteamine in treating infections caused by yeasts/moulds. - Google Patents

Use of cysteamine in treating infections caused by yeasts/moulds.

Info

Publication number
MX2017003550A
MX2017003550A MX2017003550A MX2017003550A MX2017003550A MX 2017003550 A MX2017003550 A MX 2017003550A MX 2017003550 A MX2017003550 A MX 2017003550A MX 2017003550 A MX2017003550 A MX 2017003550A MX 2017003550 A MX2017003550 A MX 2017003550A
Authority
MX
Mexico
Prior art keywords
cysteamine
yeasts
moulds
infections caused
treating infections
Prior art date
Application number
MX2017003550A
Other languages
Spanish (es)
Inventor
DUNCAN Vanessa
O'neil Deborah
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of MX2017003550A publication Critical patent/MX2017003550A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds.
MX2017003550A 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds. MX2017003550A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053523P 2014-09-22 2014-09-22
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
MX2017003550A true MX2017003550A (en) 2017-07-28

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003550A MX2017003550A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds.

Country Status (14)

Country Link
EP (1) EP3197476A1 (en)
JP (1) JP2017532317A (en)
KR (1) KR20170052613A (en)
CN (1) CN106687140A (en)
AU (1) AU2015323566B2 (en)
BR (1) BR112017005272A2 (en)
CA (1) CA2959003A1 (en)
GB (1) GB201416727D0 (en)
MX (1) MX2017003550A (en)
NZ (1) NZ730092A (en)
RU (1) RU2017108196A (en)
SG (1) SG11201701648UA (en)
WO (1) WO2016046524A1 (en)
ZA (1) ZA201701330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016288230A1 (en) * 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
MX2019008847A (en) * 2017-01-25 2019-12-16 Adare Pharmaceuticals Inc Cysteamine prodrugs.
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
CA3116637A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
CN110551637B (en) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 Echinospora echinocandii from radix astragali root for efficiently inhibiting botrytis cinerea and application thereof
CN110859950B (en) * 2019-11-25 2021-08-10 武汉大学 Pharmaceutical composition for candida albicans echinocandin drug-resistant bacteria and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
US7847059B2 (en) * 2004-08-18 2010-12-07 Novabiotics Ltd. Methods for treatment of a dermatophytic fungal infection
JP2006347990A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
JP2006347989A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
SG177750A1 (en) * 2009-08-13 2012-03-29 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
AU2015323566B2 (en) 2018-03-22
SG11201701648UA (en) 2017-04-27
BR112017005272A2 (en) 2017-12-12
WO2016046524A1 (en) 2016-03-31
JP2017532317A (en) 2017-11-02
NZ730092A (en) 2018-05-25
AU2015323566A1 (en) 2017-04-06
ZA201701330B (en) 2018-04-25
RU2017108196A3 (en) 2019-06-19
CA2959003A1 (en) 2016-03-31
KR20170052613A (en) 2017-05-12
CN106687140A (en) 2017-05-17
EP3197476A1 (en) 2017-08-02
RU2017108196A (en) 2018-10-24
GB201416727D0 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
EP3119797A4 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3263132A4 (en) Composition for treating il-6-related diseases
EP3154557A4 (en) Acellular amnion derived therapeutic compositions
GB2544342B (en) Compositions for application to wounds
MX2017008444A (en) Picolinamides as fungicides.
EP3169784A4 (en) Organic compositions to treat apoc3-related diseases
MX2017003550A (en) Use of cysteamine in treating infections caused by yeasts/moulds.
MX369357B (en) Antifungal compound process.
MX365494B (en) Antifungal compound process.
SG11201704737SA (en) Novel aqueous composition
SG10201900598TA (en) Factor viii formulation
IL249640A0 (en) Compositions for the treatment of epistaxis
EP3287010A4 (en) Composition for improving food-texture
GB201400267D0 (en) Algal bio-adhesives; compositions,process for manufacturing,formulations and uses
EP3206670A4 (en) Compositions for treating wounds
MX2016012758A (en) Hyperosmolar composition of hyaluronic acid.
IL251345B (en) Compositions for use in the treatment of peri-implantitis
ZA201608407B (en) Stain treatment compositions
ZA201606333B (en) Deactivating composition in the form of an invert emulsion
EP3212183A4 (en) Synergistic compositions for treating microbial infections
PL2965639T3 (en) Abutment unit for pieces of smokers&#39; articles
IL251590B (en) Ophthalmic compositions
ZA201608405B (en) Stain treatment compositions
PL3160263T3 (en) Compositions for preventing infections